Ligand Pharmaceuticals Incorporated focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae. The company also offers Rylaze, a recombinant erwinia asparaginase, and Nexterone, a captisol-enabled formulation of amiod
